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A deepening in the biological nature of the general factor of personality (GFP) is suggested: the activation
level of the stress system is here represented by the gene expression of c-fos. The results of a single
case experimental design are reported. A model of four coupled differential equations that explains the
human personality dynamics as a consequence of a single stimulant drug intake has been fitted to
psychological and biological experimental data. The stimulant-drug conditioning and its adaptation to
the considered mathematical model is also studied for both kinds of measures. The dynamics of the c-
fos expression presents a similar pattern to the dynamics of the psychological measures of personality
assessed by the GFP-FAS (Five-Adjective Scale of the General Factor of Personality) as a consequence
of a single dose of stimulant drug (methylphenidate). The model predicts similar dynamic patterns for
both psychological and biological measures. This study proves that describing mathematically the
dynamics of the effects of a stimulant drug as well as the effects of a conditioning method on
psychological or subjective variables and on gene expression is possible. It verifies the existence of
biological mechanisms underlying the dynamics of the General Factor of Personality (GFP).
Keywords: personality, general factor of personality, self-regulation therapy, methylphenidate, c-fos,
dynamic model.
Este artículo estudia la naturaleza dinámica del Factor General de Personalidad (FGP) en respuesta a
una dosis única de metilfenidato a partir de un diseño experimental de caso único con replicación. Para
medir el FGP, se emplean tanto medidas psicológicas (Escala de Cinco Adjetivos del Factor General
de Personalidad; ECA-FGP), como un marcador biológico (propuesto como substrato biológico del FGP)
que es la concentración del gen c-fos en los linfocitos de la sangre. También se estudia el
condicionamiento de los efectos subjetivo y biológico del metilfenidato con una técnica de sugestión y
condicionamiento, denominada terapia de auto-regulación. Por último, se propone un modelo matemático
de cuatro ecuaciones diferenciales acopladas que explican la dinámica del FGP como consecuencia
de una ingestión de droga estimulante y del condicionamiento de la droga, ajustadas a los datos
experimentales psicológicos y biológicos. Los resultados muestran un patrón dinámico similar para
ambas medidas psicológicas y biológicas del FGP en respuesta tanto a una dosis de metilfenidato
como al condicionamiento con terapia de auto-regulación. Así, se evidencia que es posible la formulación
matemática de la dinámica del FGP y sus correlatos biológicos, como el gen regulador c-fos, y su
condicionamiento mediante la terapia de auto-regulación.
Palabras clave: personalidad, factor general de personalidad, terapia de auto-regulación, metilfenidato,
c-fos, modelo dinámico.
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The genetics of the general factor of personality
Recently, the studies about the General Factor of
Personality (GFP) define a new, emergent and novel field
inside personality research. It treats about “the single general
factor hypothesis” and proposes a general factor of
personality within the five-factor model, or other personality
models, which occupies the apex of the hierarchy of
personality factors (Erdle, Irwing, Rushton, & Park, 2010;
Musek, 2007; Rushton, Borns, & Hull, 2008; Rushton et
al., 2009; Rushton & Irwing, 2008; Rushton & Irwing,
2009a,b,c,d; Schermer & Vernon, 2010; Veselka, Schermer,
Petrides, Cherkas, et al., 2009; Veselka, Schermer, Petrides,
& Vernon, 2009). Moreover, a psychometric approach to
assess the GFP from Life History Theory has been
proposed, obtaining the K-Factor, by Bogaert and Rusthon,
(1989) and Figueredo et al. (2006) and, the first
questionnaire constructed expressly to measure GFP: the
General Factor of Personality Questionnaire (GFPQ) has
been presented by Amigó, Caselles, and Micó, (2010). Also,
the first adjective scale of the GFP named Five-Adjective
Scale of the General Factor of Personality (GFP-FAS) has
been presented by Amigó, Micó, and Caselles (2009).
Some evidence about the heritability of the general
factor of personality has been found. Studies with identical
twins show that GFP has an early age of onset with 50%
of its variance attributable to non-additive (dominance)
genetic influence and the other 50 % attributable to non-
shared environmental influence (Figueredo & Rushton,
2009; Rushton et al., 2008; Veselka, Schermer, Petrides, &
Vernon, 2009). Moreover, Figueredo et al. (2006) proposed
an integrated theoretical and neuropsychological model of
the Super-K factor. They predict a common set of additive
and pleiotropic regulatory genes (K-Factor Genes) which
underlies all four phenotypic composite factors: frontal
function, personal/social function, amygdale function and
hippocampus function. But they don’t propose any specific
regulatory genes or dynamical mechanisms for the genetic
regulation of GFP. Such proposition and a mathematical
explicative model is the principal objective of this study.
Methylphenidate, activation and c-fos expression
Methylphenidate is a stimulant drug that binds and
inhibits the dopamine transporter (Gatley, Pan, Chen,
Chaturvedi, & Ding, 1996; Schweri et al., 1985) and
produces dopamine overflow in the striatum (Butcher,
Liptrot, & Arbuthnott, 1991; Gerasimov et al., 2000; Hurd
& Ungerstedt, 1989; Kuczenski & Segal, 1997; Volkow et
al., 2001). As other psycho stimulants do, the acute
administration of methylphenidate produces changes in gene
regulation, increasing the expression of the transcription
factor (immediate-early gene) c-fos in a dose-dependent
manner. Increased Fos protein levels have been detected
in different animal species such as cat (Lin, Te, Huang,
Chi, & Hsu, 1997), mouse (Penner et al., 2002) and rat
(Chase, Brown, Carrey, & Wilkinson, 2003). Also, an
increased c-fos and zif-268-mR"A levels after 2 - 20 mg/kg
(i.p.) injection has been detected in adolescent rats (Brandon
& Steiner, 2003). Besides, an increased c-fos mR"A level
is found also in adult rats after 0.5 - 10 mg/kg (i.p.) injection
(Yano & Steiner, 2005). With 5 mg/kg, c-fos mR"A levels
peaked at 40 minutes and returned to the base-line 3 hours
after injection. Similar effects are found for other stimulant
drugs (Harlan & García, 1998; Torres & Horowitz, 1999).
c-fos is a member of a family of immediate early genes
(IEGs). c-fos gene is implicated in a wide variety of
fundamental cellular processes, including mitosis,
differentiation, senescence, carcinogenesis, and neuronal
activity (Morgan & Curran, 1991). In addition, c-fos serves
as a marker of metabolic activity in individual neurons
(Akins, Liu, & Hsu, 1996; Kogure & Kato, 1993). Thus,
this gene contributes to multiple functions and represents
a physiological activation mechanism inside cells. The
expression of c-fos after focal cerebral ischemia has been
extensively studied (for a review, see Akins et al., 1996).
A rapid but transient induction of mR"A c-fos after focal
and global cerebral ischemia has been shown (Akins et al.,
1996; Kogure & Kato, 1993). Moreover, the induction of
c-fos gene products possibly enables the organism to
promote cell survival after ischemic insult (Lin et al., 1997).
Also, c-fos has been used as a neural marker of pain (Harris,
1998). Besides, stimulant drugs increase mR"A c-fos rapidly
and its level returns to the base-line after 2 or 3 hours
(Berke, Paletzki, Aronson, Hyman, & Gerfen, 1998). Testing
c-fos expression level has been used for classification of
psychoactive drugs (Sumner et al., 2004).
The scientific literature about the topic shows that the
relationship between personality and c-fos expression is
possible. Take into account that c-fos expression is
considerably increased in brain’s regions involved in the
regulation of arousal states, such as the locus coeruleus
(noradrenergic neurons) and the medial preoptic area (non-
GABAergic neurons) (Pompeiano, Cirelli, Arrighi, & Tononi,
1997). In addition, neuronal immediate-early gene
expression is regulated by synaptic activity and plays an
important role in the neuroplastic mechanisms such as
spatial learning and memory consolidation task (Bertaina-
Anglade, Tramu, & Destrade, 2000; Guzowski, Setlow,
Wagner, & McGaugh, 2001). Moreover, an increased level
of c-fos mR"A following exploration of a novel environment
has been found (Hess, Lynch & Gall, 1995; Montag-Sallaz,
Welzl, Jul, Montag & Schachner, 1999) as well as changes
in c-fos expression in human lymphocytes in response to
stress (Platt, He, Tang, Slater, & Goldstein, 1995).
Exploration of a novel environment and the patterns of
response to stress are principal characteristics of the Unique
Trait or GFP (Amigó, 2005). Because of all that, c-fos
expression can be considered as one of the possible
indicators of the GFP.
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According to the “peripheral marker hypothesis”, the
gene expression in peripheral blood lymphocytes (PBL)
reflects its expression in the brain. mR"A dopamine
receptors have been found in the human PBL (Ostadali et
al., 2004) and mR"A c-fos has been found in human PBL
(Ogard, Bratholm, Kristensen, Almdal, & Christensen,
2000). In addition, catecholamine is a critical molecular
mediator between immune and nervous systems. It transmits
information from C"S through sympathetic nerve fibers
innervating lymphoid organs (Levite, 2006).
Drug conditioning and self-regulation therapy
Since Pavlov’s experiment (1927) about drug-effects
conditioning, drug-associated conditioning responses have
been well established (Lynch, Stein, & Fertziger, 1976;
O’Brien, Childress, McLellan, & Ehrman, 1992; Stewart,
de Wit, & Eikelboom, 1984). What is more, there are
evidences about conditioned gene expression elicited by
drug-associated environmental cues. Also, marked up-
regulation of the immediate early gene product expression,
Fos, has been found during exposure to the morphine-paired
environment, (Schoeder, Holahan, Landy, & Kelley, 2000)
or cocaine-paired environment (Brown, Robertson, &
Fibiger, 1992; Neisewander et al., 2000).
The self-regulation therapy (Amigó, 1992) was created
to increase the therapeutic efficacy of the conditioning
mechanism. This procedure uses conditioning techniques
to reproduce all kinds of sensorial effect. This therapy has
been effective in order to reproduce (conditioning) stimulant
drug effects such as ephedrine effect (Amigó, 1994) or
methylphenidate effect (Amigó, 1997).
The general systems theory and the unique
personality trait theory
General Systems Theory faces several challenges in the
context of science development. One of them is to provide
new formulations to better understand complexity. A way
to understand complex systems is to model them as
differential equations systems. In this paper a model of four
coupled first order differential equations is used to explain
human personality dynamics as a consequence of a single
stimulant drug intake. The model predicts the same dynamic
patterns for both psychological and biological measures of
personality. Thus, the model reveals itself as an instrument
to unify mathematically the concept of personality dynamics
and its different psychological and biological aspects. The
adaptation of both sets of measures to a same mathematical
pattern can contribute in a future time to forecast
personality-types and to help diagnosis and therapy in
psychology and in psychiatry.
The suggested formalism is based on the Unique
Personality Trait Theory (UPTT) (Amigó, 2005). The UPTT
proposes a hierarchical model where the highest level
corresponds to the unique trait or general factor of
personality (GFP), extended from an impulsivity and
aggressively pole (approach tendency) to an anxiety and
introversion pole (avoidance tendency). In addition, this
theory asserts that personality, represented by the GFP, can
have both compatible dynamic and biological natures.
The hypothesis of the biological nature of personality
asserts that the human activation level of the stress system
is the responsible of the different responses to a stimulus.
Lower activation levels correspond with the impulsivity
and aggressively pole (approach tendency), while higher
activation levels correspond with the anxiety and
introversion pole (avoidance tendency).
The hypothesis of the dynamic nature of personality
asserts that the activation level response to a stimulus is
given by a certain time pattern that can be described
mathematically (Amigó, Caselles, & Micó, 2008a; Caselles,
Micó, & Amigó, 2010) and explains personality dynamics
as a consequence of the effect of a stimulant drug. In
addition, the study of drug conditioning is dealt as a
consequence of the consumption of a stimulant drug.
The experimental paradigm used in the performed
experiment is a single case design, such as it is described
by Barlow and Hersen, (1984). Two persons participate in
the experiment. A participant consumes two different doses
of methylphenidate. The other participant consumes a dose
of methylphenidate, whose effects will be conditioned. The
psychological response (GFP-FAS) and the biological
response (c-fos gene expression) are then evaluated. The
experimental design is presented below. Some questions
about methylphenidate, c-fos and the conditioning technique
are discussed in the context of the goals of the study, in
the next section.
Goals of this study
The first goal of this paper is to deepen in the biological
nature of personality: the activation level of the stress system
is here represented by the gene expression of c-fos. In
addition, the dynamics of the c-fos expression presents a
similar pattern to the dynamics of the psychological
measures of personality, assessed by the Five-Adjective
Scale of the General Factor of Personality (GFP-FAS)
(Amigó, Micó et al., 2009). This Scale is constituted by
five adjectives selected from the Sensation Seeking Scale
(SSS) of the MAACL (Zuckerman & Lubin, 1965). Several
combinations of adjectives of this scale have revealed to
be highly related with the GFP (Amigó, Micó, & Caselles,
2008). In addition, they are a good measure of the GFP in
state-format (Amigó, Micó et al., 2009). Showing the similar
patterns contributes to strengthen the concept of unique
trait or GFP presented by Amigó, (2005) and Amigó et al.,
(2008a), as well as to unify the same concept both from
the biological and the psychological perspectives in an only
conceptual system.
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The second goal of this paper is to present an
experimental verification of a model that reproduces the
effect of methylphenidate. The gene expression measured by
the c-fos levels in blood and, the psychological measures
assessed by the GFP-FAS scores, performed in two
experimental subjects in response to methylphenidate
challenge, are confirmed to fit the model. This model is a
generalization obtained from the one presented by Amigó et
al. (2008a). Moreover, some ideas about the present article
are taken from the paper of Amigó, Caselles, and Micó
(2008b), where the psychological effects of caffeine, measured
as well by the GFP-FAS, are studied, and a mathematical
dynamic model of gene expression produced by caffeine is
suggested. As a consequence, the dynamic nature of
personality has been indicated by the time patterns obtained.
The empirical verification of this mathematical model has
been reinforced recently with an experiment concerning the
dynamics of the GFP as a result of a single dose of caffeine
(Caselles, Micó, & Amigó, 2011).
A third goal of the present paper is to study the stimulant
drug conditioning and its adaptation to the mathematical
model for both kinds of measures. There is empirical
evidence about the conditioning of the dynamics of the GFP
as a result of methylphenidate intake by means of self-
regulation therapy, over both subjective effect and increase
of glutamate in blood (Amigó, Caselles et al., 2009). The
adaptation of both biological and psychological measures
to the same mathematical explanation for its evolution can
contribute to create a procedure to forecast personality-types
as a consequence of certain stimuli and a formal tool to help
diagnosis and therapy in psychology and in psychiatry.
In Section 2 the experimental design is described. In
Section 3 the experimental results are discussed qualitatively
from the UPTT perspective. Section 4 is devoted to summarize
the mathematical model that is going to be verified. In the
Section 5 this model is verified from the experimental results.
In Section 6 the paper conclusions are stated.
Method
Participants
Two male participants with ages of 45 and 46 years old
participated in the experiment. They are two voluntaries of
the university teaching staff.
Instruments
– General Factor of Personality Questionnaire (GFPQ)
(Amigó et al., 2010).
– Five-Adjective Scale of the General Factor of
Personality (GFP-FAS, Amigó, Micó et al., 2009). The 5
adjectives are: adventurous, daring, enthusiastic, merry
and bored.
– Biological analysis. Firstly, the blood samples were
obtained and lymphocytes were isolated by density
centrifugation on Lymphoprep. Finally, an automated mass
spectrometry platform (Sequenom, MassARRAY
Quantitative Gene Expression) was used for quantification
of the c-fos concentration in lymphocytes. β-actin was used
as internal standard R"A.
Two versions of the GFP-FAS were used: trait-format
version and state-format version (“Are you like this at this
moment?” or “do you feel so at this moment?”). Both
participants filled out the state-format version form each
fifteen minutes to obtain a situational measure of the GFP.
As it has been stated above and explained in other side
(Amigó, Micó et al., 2009), the GFP-FAS is considered in
this study as a good approximation to the GFP in state-format.
Experimental design and procedure
Firstly, both participants filled out the GFPQ and the
GFP-FAS (trait-format).
An ABC single case experimental design with replication
was used. In all of these phases the participants compliment
the GFP-FAS each fifteen minutes (17 registers each phase)
and peripheral blood samples were obtained each one hour
(5 samples each phase).
Phase A is the base-line, without treatment. In phase B
the participants received a dose of 20 mg of methylphenidate
immediately after filling out the first GFP-FAS. At the same
time, the first blood sample was obtained. In the following,
the participants complimented 16 GFP-FAS, one each fifteen
minutes and, a blood sample was obtained once per hour
along 4 hours.
In phase C, the GFP-FAS registers and the blood
samples are obtained as in phase B, but other experimental
conditions are different for both participants. Participant 1
takes 40 mg of methylphenidate immediately after
complimenting the first GFP-FAS. Next, the first blood
sample is obtained. In the following, like in phases A and
B, a blood sample is obtained from both participants each
hour along 4 hours, after filling out the corresponding GFP-
FAS. Participant 1 fills out the GFP-FAS every 15 minutes
during the 4 hours (16 GFP-FAS). Participant 2 also fills
out the GFP-FAS every 15 minutes during the 4 hours but,
for this participant, phase C is divided into two parts: base-
line (C1) and self-regulation therapy (C2). After the first
hour and 45 minutes, participant 2 applies himself the self-
regulation therapy to try to reproduce the drug effects
obtained in phase B. Note that, in the mathematical model
presented in this paper, the value of M (dose) corresponds
to the amount of methylphenidate in phases B and C of
participant 1 and in phase B of Participant 2. However, in
the self-regulation therapy, the value of M is given by the
therapy-predisposition variable, whose scale is [0, 10]. The
therapy-predisposition variable takes the value M = 8.0 in
the self-regulation therapy for Participant 2 in Phase C.
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The sequence of the experiment is:
• First day (the participants go to the medical laboratory).
Phase A: base-line.
• Second day (a week later). Phase B: the participants
take 20 mg of methylphenidate.
• Third day (a week later). Phase C: Participant 1 takes
40 mg of methylphenidate, and Participant 2 reproduces
the stimulant effects with the self-regulation therapy (C2)
after a phase of base-line (C1).
Results
This study is based on a single case experimental design
with replication. This design allows making an exhaustive
and intensive study from the perspective of unique case. And
this perspective is necessary when a new or still little-usual
research method such as the detection of regulating genes
in blood like answer to a dose of a stimulating drug is. In
addition, this study tries to develop a dynamic mathematical
model from the theory of systems to explain and to predict
the results. For that reason, this section is especially
exhaustive and displays a good amount of tables and figures.
These tables and figures show qualitative and descriptive
results, and the differences between the data obtained from
blood samples and those simulated with a dynamic model,
and can firmly orient the future research using group designs.
Qualitative discussion of the experimental results
The percentile of the scores of both participants on the
GFPQ and the GFP-FAS Trait-Format are shown in Table
1. The percentiles have been obtained from large samples
(Amigó, Micó et al., 2009; Amigó et al., 2010).
Nevertheless, in the two questionnaires, participant 1
scored higher than participant 2. The difference is better
observed in the GFPQ. In this work, GFP-FAS and GFPQ
scores are representative of the psychological expression
of the activation level of the human stress system. The
Unique Personality Trait Theory predicts that the phasic
activation following a stimulant intake will be higher in
participant 1 than in participant 2.
Figure 1 shows the GFP-FAS scores for participant 1
in each one of the three phases of the experiment. In both
Phases B (20 mg) and C (40 mg) an inverted U pattern is
observed. Such pattern is not observed in Phase A (base-
line). The curve corresponding to Phase B reaches a higher
peak than the peak reached by the curve corresponding to
Phase C. This difference indicates a greater subjective
response in the psychological expression of the activation
level.
Figure 2 shows the c-fos measures for the three phases
of participant 1. A very high difference is observed between
the inverted U curves of Phases B (20 mg) and C (40 mg)
and the U shape of Phase A (base-line). Observe also that,
qualitatively, the pattern obtained in Figure 1 and Figure 2
is similar. This outcome represents equivalence between
the psychological and the biological expressions of
personality. However, in Figure 2, a greater response of the
c-fos measure is observed in Phase C respect to Phase B,
oppositely to what Figure 1 shows. Here, a discrepancy
between the psychological and the biological measures is
observed. In Phase C the participant increases his c-fos
level while the self-informed activation is lower. An
explanation of this difference can be that the biologic
response, when the dose is doubled, is generally greater
than the subjective response. This is a question to be
investigated.
Figure 3 shows the GFP-FAS scores of Participant 2 in
each one of the three experimental phases. In Phases B (20
mg) and C (conditioned response) a response pattern
(inverted U-shape) very different than the base-line pattern
is observed. In Phase C the conditioning technique is applied
after the first hour and 45 minutes from the beginning of
the experiment (Phase C2). The effect takes an hour. A
further final increase is observed, although, the subjective
experience was pleasant and quiet rather than activating.
In this hour a peak in GFP-FAS scores greater than the one
corresponding to Phase B is observed, as well as a decrease
of the activation level deeper than the one corresponding
to Phase B.
Table 1
The percentile of the scores of the participants in the
experiment. GPFQ = General Factor of Personality
Questionnaire; GFP-FAS = Five-Adjectives Scale of the
General Factor of Personality
GFP-FAS GFPQ
Participant 1 95 85
Participant 2 80 40
Figure 1. GFP-FAS scores in the experimental phases A, B and
C for participant 1.
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Figure 2. c-fos mR"A expression in phases A, B and C for
participant 1.
Figure 3. GFP-FAS scores in phases A, B and C for participant 2.
Figure 4. c-fos mR"A expression in phases A, B and C for
participant 2.
Figure 5. c-fos mR"A for the base-line and the conditioned
response for participant 2.
Figure 6. GFP-FAS scores in phases A, B and C for participants
1 and 2.
Figure 7. c-fos mR"A scores in phases A, B and C for participants
1 and 2.
Figure 4 shows the c-fos measures in the three phases
for participant 2. A drastic change in the response pattern
in Phase B (U-inverted shape) respect to the base-line is
observed. In Phase C, a decrease pattern in mR"A c-fos is
as well observed from the third hour, i.e., when the
conditioning technique was applied (Phase C2). This pattern
is similar to the one produced by the drug, but with a much
lower magnitude.
Observing jointly the GFP-FAS scores and the mR"A
c-fos measures for Phases B and C of participant 2, a similar
pattern between the subjective response and the c-fos
expression is detected in Phase B. However, the c-fos
expression is much lesser than the subjective response in
Phase C. This difference confirms that the biological
conditioning is weak, but the conditioning of the subjective
activation is high.
Figure 5 shows, by means of a bar diagram, the base-
line of the c-fos expression (Phase A) and the conditioning
therapy-effect on the c-fos expression (Phase C) for
participant 2. Observe that from the third hour, when the
conditioning therapy is applied, the results show a level in
Phase C higher than in Phase A. This difference suggests
that a conditioning effect on the c-fos expression has been
produced as a consequence of the previous administration
of methylphenidate. This effect is weak and will have to
be confirmed in future studies. In addition, the highest
difference is produced during the second hour, when the
conditioning therapy has not yet been applied. A possible
explanation of the c-fos increase is the expectation of the
participant previous to the conditioning therapy.
Such as it can be observed in Figure 1 for participant
1, a difference between the GFP-FAS scores (subjective)
and the c-fos expression (biological) exists. Note that the
mR"A c-fos level is higher in Phase C (40 mg) than in
Phase B (20 mg), and the subjective response is lower. A
way to deeper analyze this outcome is to compare the
responses of both participants. Figure 6 shows that the
subjective response of participant 1 is higher, but delayed
with respect to the one corresponding to participant 2 in
Phase B. However, the pattern of the c-fos expression in
Figure 7 shows a delayed but shorter-in-time response for
participant 2 when compared with participant 1 in Phase
B. In the following figures and for more clarity in
comparisons, phases C1 and C2 of participant 2 are joined
as an only phase C.
In addition, Figure 8 shows two similar patterns: the
one corresponding to the GFP-FAS scores of participant 1
in Phase C (40 mg) and the one corresponding to participant
2 in Phase B (20 mg).
Moreover, Figure 9 shows a c-fos expression pattern in
Phase C of participant 1 similar to the one corresponding
to Phase B of participant 2. However, the peak of the curve
is slightly higher in participant 1. In Figures 6-9, a similar
response pattern is observed between Phase C of participant
1 and Phase B of participant 2, for both subjective (GFP-
FAS) and c-fos expression.
Descriptive and differential statistics
In tables 2 and 3, the U of Mann-Whitney between the
different experimental conditions is presented for both
participants. For participant 1, the score in GFP-FAS in
relation to its base-line increases, as with 20 mg as with
40 mg of methylphenidate but, comparing the scores
between phases B and C, we see as 20 mg of
methylphenidate increase significantly more the score in
GFP-FAS than 40 mg (possible effect of habituation). For
participant 2, the score in GFP-FAS increases significantly
with 20 mg of methylphenidate (B) and with self-regulation
therapy (C2) in comparison with its respective base-lines
(A and C1).
The percentage of low scores (0-1) and high scores (4-
5) of each one of the five adjectives for both participants
and all the experimental conditions are shown in tables 4
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Figure 8. GFP-FAS scores for participant 1 (phase C, 40 mg) and
participant 2 (phase B, 20 mg).
Figure 9. c-fos mR"A for participant 1 (phase C, 40 mg) and
participant 2 (phase B, 20 mg).
and 5. We can observe in participant 1 that, no adjective
scores high in phase A while, in phase B, all adjective-
scores increase with the same proportion (16.7% between
4 and 5) and in phase C, all they lower of similar form,
“merry” staying a bit higher.
In participant 2, only “bored” reaches a low (2.1%)
percentage of answers between 4 and 5. The dose of 20
mg of methylphenidate (B) increases the percentage of
answers between 4 and 5 for “daring” and “enthusiastic”
and, between 0 and 1 for “bored”. But in C2 (self-regulation
therapy), the percentage of scores between 4 and 5 is
reduced, in relation to B, except for “merry”, that increases
from 8.4% to 10.4%. Therefore, we have observed different
patterns of answer for each one of the adjectives and
experimental conditions in each one of the participants. As
far as self-regulation therapy, in comparison with the effect
of the 20 mg of methylphenidate, it reduces the high scores
(0 to 5) but increases the percentage of high scores in
“merry”.
The mathematical model
Amigó et al., (2008a) demonstrate that the dynamic effect
produced by a stimulant drug on the activation level of an
individual is leaded by a coupled set of three differential
equations: two ordinary differential equations that describe
the dynamics of the drug stimulus and a discrete-delay
differential equation that describes the dynamics of the
activation level. The activation level characterizes
quantitatively the GPF, which can be either psychological
(measured by the GFP-FAS scores) or biological (measured
by the c-fos expression). The dynamic model provided by
these coupled set of three differential equations is congruent
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Table 2
Mann-Whitney U to differences between experimental
conditions. Case 1. A: Base-line; B: Methylphenidate 20
mg; C: Methylphenidate 40 mg.
CASE 1
U Average range p
A 9.56
17 .001
B 23.44
A 11.34
45.5 .002
C 21.66
B 19.81
75 .045
C 13.19
Table 3
Mann-Whitney U to differences between experimental
conditions. Case 2. A: Base-line; B: Methylphenidate 20
mg; C1: Base-line; C2: Self-regulation Therapy
CASE 1
U Average range p
A 11.31
45 .002
B 21.69
C1 30 4 .001
C2 12
Table 4
Low (0-1) and high (4-5) scores to five adjectives and experimental conditions. Case 1
ADJECTIVES SCORE A B C
0-1 31.3 6.3 12.5
Adventurous
4-5 0 16.7 4.2
0-1 27.1 10.4 10.4
Daring
4-5 0 16.7 4.2
0-1 18.8 6.3 10.4
Enthusiastic
4-5 0 16.7 6.3
0-1 29.2 8.3 12.5
Merry
4-5 0 16.7 8.3
0-1 2.1 21.5 27.1
Bored
4-5 0 0 2.1
with the model by Grossberg (2000), which predicts a
different phasic reaction in response to the previous arousal
level according to an inverted-U function. This is also the
conclusion of the Opponent-Process Theory by Solomon
and Corbit (1974) to explain the acute effect of drugs. To
examine any detail about the process to obtain the model,
consult the work of Amigó et al., (2008a).
This paper presents a model of four (instead of three)
coupled differential equations obtained by transforming the
model of Amigó et al., (2008a) into a continuous-delay
(instead of discrete-delay) differential equations system.
The need of such transformation is explained below. A
summary of the model’s mathematical skeleton is presented
in the following, as well as the interpretation of any equation
and the way to convert the model of Amigó et al., (2008a).
The discrete-delay differential equation for the activation
level variable presented in the paper of Amigó et al., (2008a)
is the following:
Where:
• y(t), b and y0 are respectively the activation level
variable, its tonic level and its initial value.
• a(b-y(t)) represents the homeostatic control which
tends to fast recover the tonic activation level after a
deviation, being a the “power” of this control.
• p·s(t)/b represents the excitation effect of the stimulus
s(t) which tends to increase the activation level, being p
the “power” of this stimulus.
• τ is the inhibitor effect delay (the delay the inhibitor
effect needs to begin working).
• q·b·s(t-τ)·y(t-τ) represents the inhibitor effect, which
tends to slowly decrease the activation level, being q the
“power” of this effect.
• s(t) is the stimulus-variable that can represent the
amount of drug in blood. If c(t) is the non-assimilated drug
by blood, s(t) and c(t) are computed by the following two
coupled differential equations:
Where:
• M is the amount of the drug intake, and α is the drug
absorption rate.
• s0 is the amount of drug present in blood before the
present intake, and β is the drug distribution rate.
The parameters of the model (α, β, a, b, p, q, τ)
depend on the individual biology and the type of stimulus
(drug).
The functional dependence on time of s(t), as a
consequence of integrating (2) and (3), is:
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Table 5
Low (0-1) and high (4-5) scores to five adjectives and experimental conditions. Case 2
ADJECTIVES SCORE A B C1 C2
0-1 8.3 2.1 14.6 0
Adventurous
4-5 0 8.3 0 8.4
0-1 8.3 4.2 14.6 0
Daring
4-5 0 14.6 0 8.4
0-1 31.2 18.7 14.6 4.2
Enthusiastic
4-5 0 12.6 0 8.4
0-1 31.2 14.6 14.6 8.4
Merry
4-5 0 8.4 0 10.4
0-1 0 23 0 14.6
Bored
4-5 2.1 0 2.1 0
(1)
(2)
(3)
(4)
METHYLPHENIDATE AND SELF-REGULATION THERAPY 859
The differential equation (1) has an analytical solution
(see Amigó et al., 2008a) that depends on definite integrals
and can be programmed for a computer. The forecasted
dynamics coincides with what the opponent-process theory
proposed by Solomon and Corbit (1974) predicted to explain
the acute effect of drugs, and with the model proposed by
Grossberg (2000).
Observe that the inhibitor effect provides an “all or
nothing” delayed dynamic regulation. This dynamics is
typical of a microscopic description but not of a
macroscopic one. In order to introduce an inhibitor effect
with a continuous delay, typical of a macroscopic
description, we consider an inhibitor effect that arises from
a minimum weight (zero in the initial time), increasing
continuously up to reach a maximum weight in the
computation time. The quantification of this hypothesis
consists of considering a mathematical structure as the
following one: b · q ∫
t
0
exp ((x–t)/τ) · s(x) · y(x) · dx. This
kind of inhibitor effect can be interpreted as a continuous
sum of the product s(x) · y(x) between the initial time, t =
0 and the computation time t, with a weight given by exp
((x–t)/τ). This function is increasing in the computation
interval [0, t]. Moreover, it takes its minimum at its initial
time (that is, when x = 0) and it takes its maximum (equal
to the unit) at the computation time t (that is, when x = t)
and, it tends to zero as t → +∞. For this mathematical
structure, τ represents an adjusting time, depending on each
individual.
Considering this new inhibitor effect, Equation (1) can
be rewritten as:
Equation (5) together with equations (2) and (3) define
a continuous-delay model. However, the fact of being (5)
an integrodifferential equation makes difficult to handle the
model. In order to solve the problem a new variable is
defined:
Observe that z(0) = 0. Deriving (6) with respect to time,
equation (7) is obtained:
Substituting (6) in (5) and introducing (7) as a new
equation the following system is obtained:
The system defined by the two coupled equations (8)
and (9) together with equations (2) and (3) is the continuous-
delay model of the evolution of the activation level as a
consequence of a single intake of a stimulant drug. This
model has been tested by Micó, Amigó, & Caselles, (2008)
with the evolution of the GPF-FAS scores obtained as a
consequence of an intake of caffeine and it is here used to
describe the dynamics of the subjective activation state and
the c-fos expression of an individual, as a consequence of
a stimulant drug intake (methylphenidate).
Fitting the mathematical model
The aim of this section is to show how the mathematical
model given by equations (2), (3), (8) and (9), adapts to
the dynamic patterns of the GPF-FAS scores and of the c-
fos expression.
The model is going to be tested in the experimental
phases B for both participants and in phase C for participant
1. Phase B corresponds to an intake of M = 20 mg of
methylphenidate for both participants and, phase C of
participant 1 corresponds to an intake of M = 40 mg of
methylphenidate. In phase C of participant 2, methylphenidate
is substituted by the conditioning therapy. Being the dynamic
pattern of the effect of this therapy similar to the effect of
the drug, the mathematical model is also checked under the
hypothesis that the stimulus pattern is governed by equations
(2) and (3) but with an unknown amount M of drug.
For GPF-FAS scores, the range of the data is [0, 25],
while the data of the c-fos expression vary inside an
unknown a priori scale that seems to be inside the interval
[0, 100] (presented multiplied by 10-17).
The analytical solution of the model has been
programmed in Mathematica 7.0, and the fitting of the
model to the data has been computed by the minima square
method. The evaluation of the degree of fitting has been
performed by the computation of the determination
coefficient R2. Following this method, the optimal values
of the model’s parameters arise. These values depend on
the participant and on the kind of stimulant drug. They
depend as well on whether the activation level y(t) has a
psychological nature (GPF-FAS) or a biological one (c-fos
(5)
(6)
(7)
(8)
(9)
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expression). In Tables 6 to 9 the optimal values obtained
are represented for both participants and for both phases.
Figures 10 to 17 present the evolution curves obtained
from the fitted differential equations joined with the
experimental results (GPF-FAS scores or c-fos expression)
classified per participants. Such figures permit to observe
easily the good fit between the curves and the experimental
results and to compare the dynamics of GPF-FAS and c-
fos between participants.
For participant 1 in phase B (20 mg of methylphenidate),
Figure 10 shows the actual GPF-FAS scores and the
corresponding curve given by the model, with R2 = .97.
The fitting can be considered excellent. The same conclusion
can be deduced from Figure 11, being now the c-fos
expression fitted with R2 = .99. However, the c-fos
expression presents a final increase that differences this
pattern from the GPF-FAS pattern. Observe in Tables 6 and
7 that the absorption rate (α) and the distribution rate (β)
are the same for both GPF-FAS and c-fos expression
dynamics, that is, the dynamics of the drug in blood can
be considered as independent of the dynamics of the stress
in brain.
Figure 12 shows the GPF-FAS scores and the
corresponding model curve, with R2 = .81, for phase C (40
mg of methylphenidate) of participant 1. The real data have
more dispersion, but the residuals are random. Thus, the
fitting can be considered acceptable. The corresponding c-
fos expression in Figure 13 has a fitting degree of R2 = .99,
i.e., the real data present a slight dispersion. In this case,
the c-fos expression presents a final slight increase that
differences this pattern from the GPF-FAS pattern, similarly
to phase B. Observe again in Tables 6 and 7 that the
absorption rate (α) and distribution rate (β) are the same
for both GPF-FAS and c-fos expression dynamics. Their
values coincide also with the respective values of phase B.
It confirms that the dynamics of the drug in blood can be
considered as independent of the dynamics of stress in
brain. On the other hand, observe that, in the psychological
Table 6
Values of the parameters of the model for GFP-FAS
measures in Participant 1
PARTICIPANT 1: GFP-FAS measures
PHASE B PHASE C
M 20.0 40.0
y0 8.0 8.0
α 0.000069 0.000069
β 0.006114 0.006114
a 0.010598 0.030901
b 1.957947 1.047782
p 12.235929 5.785946
q 0.001514 0.003568
τ 490.853858 240.414747
Table 7
Values of the parameters of the model for c-fos expression
in Participant 1
PARTICIPANT 1: c-fos expression
PHASE B PHASE C
M 20.0 40.0
y0 26.87 26.95
α 0.000069 0.000069
β 0.006114 0.006114
a 0.007437 0.005667
b 3.691873 6.570634
p 113.273231 160.916231
q 0.002348 0.001374
τ 126.564076 48.265008
Table 8
Values of the parameters of the model for GFP-FAS
measures in Participant 2
PARTICIPANT 2: GFP-FAS measures
PHASE B PHASE C
M 20.0 8.0
y0 6.0 5.0
α 0.000730 0.000468
β 0.013518 0.000572
a 0.0003689 0.000212
b 8.646789 14.504409
p 6.2751 22.2305
q 0.000096 0.000287
τ 79.776 36.300103
Table 9
Values of the parameters of the model for c-fos expression
in Participant 2
PARTICIPANT 2: c-fos expression
PHASE B PHASE C
M 20.0 8.0
y0 19.9 36.0
α 0.000730 0.000468
β 0.013518 0.000572
a 0.015704 0.000165
b 20.742641 13.644298
p 144.586185 20.729941
q 0.000113 0.000533
τ 46.082587 11.049751
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Figure 10. GPF-FAS scores (points) and model curve (line) in
Phase B for Participant 1. R2 = 0.97.
Figure 13. c-fos expression (points) and model curve (line) in
Phase C for Participant 1. R2 = 0.99.
Figure 11. c-fos expression (points) and model curve (line) in
Phase B for Participant 1. R2 = 0.99.
Figure 14. GPF-FAS scores (points) and model curve (line) in
Phase B for Participant 2. R2 = 0.93.
Figure 12. GPF-FAS scores (points) and model curve (line) in
Phase C for Participant 1. R2 = 0.81.
Figure 15. c-fos expression (points) and model curve (line) in
Phase B for Participant 2. R2 = 0.99.
measures of participant 1, the greatest values are about 5
points lesser in phase C than in phase B, while in the
biological measures of participant 1 there is an increase of
5 points in phase C respect to phase B. That is, despite the
drug intake is double in phase C than in phase B, a
habituation phenomenon in psychological measures has
occurred, and contrarily, a sensitizing phenomenon has
occurred in biological measures.
For participant 2 in phase B (20 mg of methylphenidate),
Figure 14 shows the GPF-FAS scores and the corresponding
model curve, with R2 = .93, revealing a slight dispersion.
However, the fitting can be considered as good due to the
residuals are random. Figure 15, shows the fitted curve of
the c-fos expression and the experimental data, with R2 =
.99, i.e., there is an excellent fitting degree. A slight
recovery, similar to the final increase of the c-fos curves
of participant 1, must be emphasized. In addition, note
again in Tables 8 and 9 for participant 2 that the absorption
rate (α) and distribution rate (β) are the same for both GPF-
FAS and c-fos expression dynamics, that is, the dynamics
of the drug in blood shows here again to be independent
of the dynamics of stress in brain.
For participant 2 in phase C (conditioning therapy), the
mathematical dynamics of the stimulus is unknown but
produced by the conditioning therapy. The stated hypothesis
is that this dynamics can be described by Equations (2) and
(3), i.e., by the same equations than for a stimulant drug,
such as methylphenidate. Observe that the absorption rate
(α) and the distribution rate (β) must be different than in
phase B of participant 2 because no drug dynamics in blood
exists, thus, both optimal parameters’ values and the
corresponding optimal parameters’ values of Equations (8)
and (9) have all been found through the minima square
method. Tables 8 and 9 show these values. Figure 16 shows
the GPF-FAS scores obtained as a consequence of the
conditioning therapy, and the corresponding model’s curve,
with R2 = .85. The fitting can be considered as good,
because the residuals are random, although the final
tendency of the curve does not describe completely all the
actual recovering. Therefore, the cause of the abrupt
recovering of the experimental measures could be due to
other influences not considered in the model. Figure 17,
shows the fitted curve of the c-fos expression and the
corresponding experimental data, with R2 = .99, i.e., an
excellent agreement between experimental data and theory
is obtained. Observe that the hypothesis stating that the
conditioning therapy has the same dynamic-effects pattern
than the methylphenidate administration and that the
corresponding amount of drug M can be substituted by a
subjective therapy-predisposition-variable are confirmed.
Thus, the dynamics of both the psychological and the
biological dynamic patterns can be described by the same
model.
General discussion and conclusions
In this study it has been proved that it is possible to
describe mathematically the dynamics of the effects of a
stimulant drug and the effects of a conditioning method
of such effects on psychological or subjective variables
and on the gene expression. That verifies the existence of
biological mechanisms underlying the dynamics of the
General Factor of Personality (GFP) such as the Unique
Personality Trait Theory predicts (Amigó, 2005; Amigó et
al., 2008a). The Five Adjective Scale of the General Factor
of Personality (GPF-FAS) suggested by Amigó, Micó et
al. (2009) in state-format was used to measure the
subjective effects that a stimulant drug (methylphenidate)
produces. The participants in the experiment filled the
corresponding questionnaire every 15 minutes during 4
hours. In order to measure the c-fos expression, its
concentration was analyzed in blood lymphocytes from
samples obtained each one hour. The self-regulation therapy
(Amigó, 1992; 1997) was used as a technique for
conditioning the effect of the drug.
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Figure 16. GPF-FAS scores (points) and model curve (line) in
Phase C for Participant 2. R2 = 0.85.
Figure 17. c-fos expression (points) and model curve (line) in
Phase C for Participant 2. R2 = 0.99.
The experiment was a single-case experiment with two
voluntary participants and three phases of 4 hours duration
each one: phase A (base line), phase B (20 mg of
methylphenidate) and phase C (40 mg of methylphenidate
for participant 1 and the conditioning technique for
participant 2). Subjective measurements (GPF-FAS) and
biological measurements (c-fos expression) were performed
in all phases.
The obtained results show that 20 mg of methylphenidate
(phase B) produce an intense psychological activation effect
in both participants with respect to the base line (phase A).
This effect has an inverted U shape, what means that 20 mg
of methylphenidate (phase B) change the psychological
activation at short term (4 hours) increasing it and later
decreasing it. Moreover, both participants modify their c-fos
expression in the same manner with respect to the base line.
Accepting that the psychological activation measured
by the GPF-FAS scale is a good approximation to a
measurement of the GFP (Amigó et al., 2009b), it can be
concluded that 20 mg of methylphenidate modify personality
at short term (4 hours) while its genetic background is
modified. This result represents a confirmation of the
integration of the dynamics of the subjective and genetic
aspects of personality as a response to a stimulant drug
intake.
Thus, the change pattern of the subjective and genetic
activation is the same after a 20 mg methylphenidate intake
(phase B) but, when a second 40 mg intake was done
(participant 1 in phase C) the correspondence between the
subjective and genetic measures was not the same than in
phase B. That is, while the genetic activation increased
respect to phase B, the psychological activation decreased.
A possible explanation of this fact may be that the increase
of the c-fos expression in phase C triggers a strong
physiological reaction inhibiting the activation.
The self-regulation therapy (as a technique of drug
conditioning) was applied at the beginning of the third hour
of the phase C of participant 2. So, such phase C is divided
into two sub-phases: base-line or sub-phase 1 (C1), during
the first two hours and, conditioning technique or sub-phase
2 (C2) during the last two hours. With respect to the
psychological activation, sub-phase 1 presents a pattern
identical to the general base-line pattern (phase A) and, sub-
phase 2 presents an increase similar, even greater, than the
one corresponding to phase B, while it decreases quickly
and afterwards increases a little bit. That may be due to the
fact that participant 2 manifested that felt very activated and
energetic at the beginning and with an agreeable sensation
of peace and wellbeing at the end. That is, the activation
was not reduced but transformed from energy to quite
wellbeing. On the other hand, sub-phase 1 presents a strong
increase of c-fos level with respect to phase A (base line)
that may be due to the expectation of receiving the
conditioning technique (participant 2 knew it); and sub-
phase 2 presents an increase of the c-fos level with respect
to phase A but much lesser than the one produced in phase
B. Summarizing, the effect of the conditioning technique
on the c-fos expression is light and must be considered with
caution. Nevertheless, the conditioning of the increment of
glutamate in blood has been obtained with the self-regulation
therapy (Amigó, Caselles et al., 2009). This fact suggests
that to investigate about other neurotransmitters or genes as
biological substrates of the GPF and which can be
conditioned by the self-regulation therapy can be interesting.
Observe that in all presented figures and for both
participants the same type of relation between the
psychological and genetic activations exists: they present
the same increasing trend during the first two hours but,
the psychological activation falls slowly during the next
two hours while the genetic activation falls much faster
towards a level lower that the initial one and recovers slowly
the initial level. That may be interpreted saying that the c-
fos increase starts different physiological activation systems
that maintain the activation during a long time in spite of
the fast degradation of the regulator gen.
Observe also that there are some differences between
the change patterns of both participants. The UPTT predicts
that the phasic response to a stimulant drug will be greater
in persons with a greater GFP. Consequently, participant 1,
with a higher percentile than participant 2 (85 and 40
respectively), should have to present a higher phasic
response. This fact is found in phase B while the
corresponding results in phase C suggest a possible
habituation in participant 1. Thus, in phase B, participant 2
increases his psychological and genetic activation faster than
participant 1 in phase C. Furthermore, the psychological
and genetic activation pattern is the same in both participants
when comparing phase C of participant 1 with phase B of
participant 2, that is, the activation produced by 20 mg of
methylphenidate in participant 2 is almost the same than
the one produced by 40 mg of methylphenidate in participant
1. In other words, the activation of participant 1 with 20
mg of methylphenidate is greater than the one of participant
2 with the same dose but, the activation of participant 1
with 40 mg of methylphenidate is similar than the one of
participant 2 with 20 mg of methylphenidate. That is, the
psychological and genetic activation produced by
methylphenidate is regulated by the dose, by the past intakes
and by the type of individual.
Summarizing, this study, that presents a single case
experimental design with two participants, shows that it is
possible to describe mathematically the change pattern of
the activation (as psychological one as genetic one)
produced by a given dose of a stimulant drug such as
methylphenidate. It is also possible to reproduce the
activation (mainly the psychological one) produced by
methylphenidate with self-regulation therapy. This fact
opens good expectations about therapeutic applications of
the here obtained results. A precedent can be found in a
clinical study where self-regulation therapy was applied to
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reproduce the effect of methylphenidate for reducing anxiety
and depression (Amigó, 1997). Personality is a system that
integrates all systems of the human being, as psychological
as biological ones. Starting from the hypothesis of the
existence of a unique and dynamical personality trait or
General Factor of Personality (Amigó, 2005; Amigó et al.,
2008a) that corresponds to the general activation of the
organism, it has been demonstrated that this activation can
be measured as well with adjective scales as with the level
of expression of c-fos. The existence of a correspondence
between the change patterns of psychological activation
and genetic activation as a response to methylphenidate has
been pointed out (although psychological activation carries
on for a longer time). Furthermore, such patterns depend
on variables such as: the subject, the dose and, the
consumption’s history.
With respect to limitations of this study and to future
research, in this paper, the influence of the subject, the dose
and, the consumption’s history over the response to
methylphenidate have been studied for single cases but, the
study for groups in order to generalize the results remains
for future research. In addition to increment the number of
experimental subjects, it is necessary to design intra and
inter-individuals experiments to test some of the hypothesis
and assumptions, as biological ones as mathematical ones,
which this exhaustive (it is an experimental design with
replication and not a simple case study) single case study
has provided. Also, it will be interesting for future research
to consider other regulatory related genes (such as DRD2
and DRD3 for instance) to check the combined effects
between activator and inhibitor genes on physiological
activation and on psychological activation. Another
interesting research line is to test the suggested mathematical
model with the effects of other stimulant drugs and with
sedative drugs to check if it is able to explain and predict
its action mechanisms.
This study shows that personality, and concretely the
GFP, measured through the psychological and genetic
activation, changes as a response to a certain dose of a
stimulant drug and, that this change can be reproduced by
conditioning techniques. Consequently, it represents the
beginning of a research line to describe and predict the
personality changes and to analyze with detail the short-
term genetic-expression evolution, applying the “peripheral
marker hypothesis” as an underlying personality factor.
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